What was the major update for Racura Oncology (ASX:RAC) on May 15, 2026?

Racura Oncology received clearance from its Safety Review Committee to advance its Phase 1 CPACS clinical trial to the next dosage level.

Why is the dose escalation for RC220 significant for investors?

Dose escalation is a critical de-risking step in early-stage biotech trials as it demonstrates that the drug is well-tolerated at lower levels.

What were the safety results for Racura Oncology’s Cohort 1 patients?

The Safety Review Committee reported an absence of dose-limiting toxicities (DLTs) in the initial patient group, despite these patients having advanced metastatic solid tumours.

What is the core investment thesis for RC220?

The primary objective of RC220 is its "cardioprotective potential," meaning it aims to protect the heart from the damaging side effects of anthracycline chemotherapies like doxorubicin.

How did the trial protocol change for Racura Oncology (ASX:RAC) Cohort 2?

The trial protocol has been updated to include an initial lead-in monotherapy cycle of doxorubicin before the patient receives RC220.

Where is the CPACS clinical trial currently being conducted?

Racura Oncology is currently screening and enrolling new patients for Cohort 2 across clinical sites in Australia, Hong Kong, and South Korea.

Racura Oncology cleared to double RC220 trial dosage

Published May. 15 2026Last Updated May. 15 2026

Racura Oncology (ASX:RAC) announced a milestone in its Phase 1 CPACS clinical trial, receiving formal clearance to escalate the dosage of its lead candidate, RC220.

Following a data review by the Safety Review Committee, the trial is set to transition from Cohort 1 to Cohort 2, doubling the RC220 dose from 40mg/m2 to 80mg/m2.

The SRC’s decision comes after evaluating the safety and pharmacokinetic profiles of the initial patient group, all of whom presented with advanced metastatic solid tumours.

The committee reported an absence of dose-limiting toxicities, even when RC220 was administered alongside the standard-of-care chemotherapy agent, doxorubicin.

Racura CEO Dr Daniel Tillett expressed strong optimism, noting that the safety profile observed thus far is "highly encouraging" given the advanced nature of the patients' conditions.

Under an updated trial protocol, Cohort 2 will incorporate an initial lead-in safety monotherapy cycle of doxorubicin before RC220 administration.

The adjustment allows researchers to utilise a blood-based molecular test to specifically assess RC220’s anthracycline cardioprotective potential—a key objective of the trial.

Screening for new participants is currently active across clinical sites in Australia, Hong Kong, and South Korea.

As the trial progresses, existing patients from the first cohort will be transitioned to the updated protocol to ensure consistency in data collection regarding the drug’s ability to protect the heart during intensive anticancer treatment.

At the time of reporting, Racura Oncology’s share price was $2.86.